HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats.

Abstract
Two cannabinoid (CB) receptor subtypes, CB1 and CB2, have been cloned and characterized. Among other activities, receptor activation by cannabinoid ligands may result in pro- or antifibrogenic effects depending on their interaction with CB1 or CB2, respectively. In the current study, we investigated whether selective activation of hepatic CB2 modifies collagen abundance in cirrhotic rats with ascites. mRNA and protein expression of CB receptors in the liver of control and cirrhotic rats was assessed by reverse transcription-polymerase chain reaction, Western blot, and immunohistochemistry. The effect of chronically activating the CB2 receptor was investigated in cirrhotic rats with ascites treated daily (9 days) with the CB2 receptor-selective agonist 3-(1,1-dimethylbutyl)-1-deoxy-Delta(8)-tetrahydrocannabinol (JWH-133). At the end of treatment, mean arterial pressure and portal pressure were measured, and liver samples were obtained to evaluate infiltrate of mononuclear cells, hepatic apoptosis, alpha-smooth muscle actin (SMA) expression, collagen content, and matrix metalloproteinase (MMP)-2 abundance in all animals. JWH-133 improved arterial pressure, decreased the inflammatory infiltrate, reduced the number of activated stellate cells, increased apoptosis in nonparenchymal cells located in the margin of the septa, and decreased fibrosis compared with cirrhotic rats treated with vehicle. This was associated with decreased alpha-SMA and collagen I and increased MMP-2 in the hepatic tissue of cirrhotic rats treated with the CB2 agonist compared with untreated cirrhotic animals. Therefore, selective activation of hepatic CB2 receptors significantly reduces hepatic collagen content in rats with pre-existing cirrhosis, thus raising the possibility of using selective CB2 agonists for the treatment of hepatic fibrosis in human cirrhosis.
AuthorsJavier Muñoz-Luque, Josefa Ros, Guillermo Fernández-Varo, Sònia Tugues, Manuel Morales-Ruiz, Carlos E Alvarez, Scott L Friedman, Vicente Arroyo, Wladimiro Jiménez
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 324 Issue 2 Pg. 475-83 (Feb 2008) ISSN: 1521-0103 [Electronic] United States
PMID18029545 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Cannabinoids
  • Receptor, Cannabinoid, CB2
  • 1,1-dimethylbutyl-1-deoxy-Delta(9)-THC
Topics
  • Animals
  • Cannabinoids (pharmacology, therapeutic use)
  • Fibrosis
  • Liver (drug effects, metabolism, pathology)
  • Liver Cirrhosis (drug therapy, metabolism, pathology)
  • Male
  • Rats
  • Rats, Wistar
  • Receptor, Cannabinoid, CB2 (agonists, biosynthesis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: